Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
Nano Lett ; 23(2): 619-628, 2023 01 25.
Article in English | MEDLINE | ID: covidwho-2185488

ABSTRACT

Anti-spike neutralizing antibodies (S NAbs) have been developed for prevention and treatment against COVID-19. The nanoscopic characterization of the dynamic interaction between spike proteins and S NAbs remains difficult. By using high-speed atomic force microscopy (HS-AFM), we elucidate the molecular property of an S NAb and its interaction with spike proteins. The S NAb appeared as monomers with a Y conformation at low density and formed hexameric oligomers at high density. The dynamic S NAb-spike protein interaction at RBD induces neither RBD opening nor S1 subunit shedding. Furthermore, the interaction was stable at endosomal pH. These findings indicated that the S NAb could have a negligible risk of antibody-dependent enhancement. Dynamic movement of spike proteins on small extracellular vesicles (S sEV) resembled that on SARS-CoV-2. The sensitivity of variant S sEVs to S NAb could be evaluated using HS-AFM. Altogether, we demonstrate a nanoscopic assessment platform for evaluating the binding property of S NAbs.


Subject(s)
COVID-19 , Humans , SARS-CoV-2 , Spike Glycoprotein, Coronavirus , Antibodies, Viral , Antibodies, Neutralizing
2.
Cells ; 10(6)2021 06 07.
Article in English | MEDLINE | ID: covidwho-1259432

ABSTRACT

The host nucleocytoplasmic trafficking system is often hijacked by viruses to accomplish their replication and to suppress the host immune response. Viruses encode many factors that interact with the host nuclear transport receptors (NTRs) and the nucleoporins of the nuclear pore complex (NPC) to access the host nucleus. In this review, we discuss the viral factors and the host factors involved in the nuclear import and export of viral components. As nucleocytoplasmic shuttling is vital for the replication of many viruses, we also review several drugs that target the host nuclear transport machinery and discuss their feasibility for use in antiviral treatment.


Subject(s)
Cell Nucleus/metabolism , Cell Nucleus/virology , SARS-CoV-2/physiology , Virus Physiological Phenomena , Virus Replication/physiology , Active Transport, Cell Nucleus/physiology , COVID-19/metabolism , COVID-19/virology , Host-Pathogen Interactions/physiology , Humans , Nucleocytoplasmic Transport Proteins/metabolism , Virus Internalization , Viruses/pathogenicity
SELECTION OF CITATIONS
SEARCH DETAIL